To define whether EPIC1 is involved in TMZ resistance in glioma cells, we performed the MTT assay in EPIC1 siRNA or EPIC1 plasmid transfected glioma cells followed by TMZ treatment. This evidence concerns the gene EPIC1 and central nervous system cancer.